Linden Capital Partners acquires Chesapeake

Chesapeake IRB ("Chesapeake") the leading provider of technology enabled independent institutional review board ("IRB") services to the clinical research industry, is pleased to announce it has been acquired by Linden Capital Partners ("Linden"), a Chicago-based healthcare private equity firm that invests world-class resources in exceptional healthcare companies.

"With a superb reputation, skilled management team, and unique technologies and capabilities, Chesapeake is well-positioned to continue to provide high quality IRB services across the clinical research and development spectrum," said Linden Operating Partner Pat Donnelly, a 20-year pharma services veteran, who previously was President and CEO of PRA International and Chairman and CEO of Aptiv Solutions. He will join the Chesapeake Board of Directors as Chairman. John Potthoff, most recently the President and CEO of Theorem Research, will also join the Chesapeake Board of Directors, further enhancing Chesapeake's depth and breadth of clinical reach.

Jeffrey Wendel, the President and CEO of Chesapeake IRB said, "We look forward to leveraging Linden's significant resources and expertise as we continue to focus on delivering exceptional quality and customer service to our research partners."

"We are pleased to be partnering with Jeff, his talented management team, and Chesapeake's outstanding workforce. Together, they have successfully built Chesapeake into a leader in the IRB space, and we look forward to supporting them in their ongoing growth initiatives," said Tony Davis, President and Managing Partner at Linden.